GARD™

 

Genetic Alzheimer’s Risk Discovery (GARD™)

GARD™ is a genetic test for multiple genetic polymorphisms (variants) associated with increased risk of the most common form of dementia: late-onset Alzheimer’s disease. GARD™ combines genetic assessment of genetic polymorphism for several key genes: apoliprotein E (ApoE), interleukin-10 (IL-10) and interleukin-6 (IL-6) with additional genes being added as development progresses. Genetic variants associated with Alzheimer’s disease are found in important proteins such as ApoE which is involved in many different aspects of neuronal activity, survival and death. Other proteins critical in the neuro-degeneration include the cytokines which are involved in inflammation and their genetic polymorphism can contribute to either enhanced or decreased risk of developing Alzheimer’s disease depending on the type of polymorphism. Two multifunctional cytokines, IL-6 and IL-10 are very relevant. IL-6 is a potent pro-inflammatory cytokine while IL-10 acts to limit inflammation in the brain. Combination of genetic polymorphisms of ApoE, IL-10 and IL-6 as used in GARD™ test determines the grade of risk to Alzheimer’s disease and facilitate the choice of possible interventions.

The e4 allele of the APOE gene is the strongest genetic risk factor for late-onset Alzheimer’s disease; people with two ApoE4 copies have a 25-fold increased risk for developing the disease compared to ApoE3/ApoE3 carriers. Certain combinations of IL-10 and IL-6 polymorphisms can increase risk 10-fold.

APO-E, IL-6 AND IL-10 are independent risk factors. Moreover, with additional single nucleotide polymorphisms (SNPs) being added, GARD™ is expected to have a very high predictive value.

 

GARD Test

Test detects multiple genetic polymorphisms including ApoE, IL-6 and IL-10, all associated with increased risk of late-onset Alzheimer’s Disease.

Patent granted in most territories.

 

Preliminary data from the currently ongoing clinical trial conducted by ImmunoClin provide confirmation of the current development strategy. This trial includes Alzheimer’s patients who experience different rate of disease progression as well as aged matched healthy controls. Knowing the risk is increasingly being recognized as a positive fact as the growing scientific and clinical evidence suggests that early interventions are most successful if the patients at risk can be identified.

In addition, even in the absence of effective drugs, changing life style and diet can be highly effective in preventing or alleviating many disorders.

 

IMMUNOLOGY News

April 21-23, 2016 Dubai, United Arab Emirates
6th Global Experts Meeting & Expo on Nanomaterials and Nanotechnology 
Learn More

August 21-26, 2016 Melbourne, Australia
International Congress of Immunology
Learn More

August 22-25, 2016 in Sendai City, Miyagi, Japan
16th International Conference on Nanotechnology: Green Nanotechnology for a Sustainable Society
Learn More

October 3-5, 2016, London, United Kingdom
4th International Conference on Geriatrics & Gerontology
Learn More

October 9-10, 2016 Dubai, United Arab Emirates
International Congress in Aesthetics, Anti-Ageing and Medical
Learn More

October 12-13, 2016, San Francisco, California, USA
8th Annual Personalized &Precision Medicine Conference
Learn More

December, 8-10, 2016, Dubai, United Arab Emirates
7th International Conference on Clinical Nutrition
Learn More

February 15-17, 2017, Tokyo, Japan
International Nanotechnology Exhibition Conference
Learn More

February 16-17, 2017, London, United Kingdom
19th International Conference on Immunology
Learn More

June 21-22, 2017, Vienna, Austria
19th International Conference on Nanotechnology and Nanomedicine
Learn More

July 23-27, 2017, San Francisco, California, USA
International Association of Gerontology and Geriatrics Conference
Learn More

October 22-27, 2017 Buenos Aires, Argentina
21st IUNS-ICN International Congress of Nutrition
Learn More